Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMOF2C6)

• Drug Name: Ecallantide Drug Info
• Synonyms: FOV-2302; Retinal venous occlusion therapy, Fovea; Ecallantide (ophthalmic formulation/retinal disease); Ecallantide (ophthalmic formulation/retinal disease), Dyax/Fovea; DX-88 (ophthalmic formulation/retinal disease), Dyax/Fovea

Indication

Disease Entry	ICD 11	Status	REF
Retina venous occlusion	9B74.1	Approved	[1]

• Cross-matching ID:
  PubChem CID: 44152182
  CAS Number: CAS 460738-38-9
  TTD Drug ID: DMOF2C6
  ACDINA Drug ID: D01026

Molecule-Related Drug Atlas

Drug(s) Targeting Kallikrein-related peptidase (KLK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bortezomib	DMNO38U	Leukemia		Approved	[3]
Cetraxate	DMSP4JX	Peptic ulcer	DA61	Approved	[4]
LM-030	DMSJOE3	Congenital ichthyosiform erythroderma	EC20.02	Phase 2	[5]
Benzoxazinone derivative 2	DM4FHTG	N. A.	N. A.	Patented	[6]
Benzyl amine derivative 1	DMOU84B	N. A.	N. A.	Patented	[6]
Benzyl amine derivative 2	DMFK7EL	N. A.	N. A.	Patented	[6]
Heteroaryl-carboxamide derivative 11	DM1CWU7	N. A.	N. A.	Patented	[6]

Drug(s) Targeting Plasma kallikrein (KLKB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lanadelumab	DMEH7YU	Hereditary angioedema	4A00.14	Approved	[7]
Berotralstat	DMWA2DZ	Hereditary angioedema	4A00.14	Approved	[8]
KVD001	DMK4VOU	Diabetic macular edema	9B71.02	Phase 2	[9]
KVD824	DM5N4OA	Diabetic macular edema	9B71.02	Phase 2	[10]
THR-149	DMW8X05	Diabetic macular edema	9B71.02	Phase 2	[11]
(4-bromo-1H-pyrazol-1-yl)(p-tolyl)methanone	DM31OSD	Discovery agent	N.A.	Investigative	[12]
(3-nitro-1H-pyrazol-1-yl)(p-tolyl)methanone	DMT9FZD	Discovery agent	N.A.	Investigative	[12]
1-benzoyl-N-phenyl-1H-pyrazole-3-carboxamide	DMG5MNZ	Discovery agent	N.A.	Investigative	[12]
D-Pro-Phe-Arg chloromethyl ketone	DMRJQ8X	Discovery agent	N.A.	Investigative	[13]
(3,4-dichlorophenyl)(1H-pyrazol-1-yl)methanone	DMNVDLI	Discovery agent	N.A.	Investigative	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Kallikrein-related peptidase (KLK)	TT5L2VC	NOUNIPROTAC	Inhibitor	[2]
Plasma kallikrein (KLKB1)	TTMF8H9	KLKB1_HUMAN	Inhibitor	[2]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6955).
• [2] Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery. Expert Opin Biol Ther. 2008 Aug;8(8):1187-99.
• [3] Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin. J Med Chem. 1995 Apr 28;38(9):1511-22.
• [4] A new broad spectrum inhibitor of esteroproteases, 4-(2-carboxyethyl) phenyl-trans-4-aminomethyl cyclohexane carboxylate hydrochloride (DV 1006). Tohoku J Exp Med. 1972 Mar;106(3):233-48.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Serine protease inhibitors to treat inflammation: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Feb;28(2):93-110.
• [7] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [8] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] Clinical pipeline report, company report or official report of KalVista Pharmaceuticals.
• [11] Clinical pipeline report, company report or official report of Oxurion.
• [12] N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38.
• [13] Novel 3-carboxamide-coumarins as potent and selective FXIIa inhibitors. J Med Chem. 2008 Jun 12;51(11):3077-80.